Biomonitoring equivalents (BEs) draw upon existing risk assessment information for chemical compounds to provide a tool for the interpretation of biomonitoring data in a health risk assessment context. BEs are based on our understanding of the chemical’s pharmacokinetics (how the chemical is absorbed, distributed, and altered in the body and how it is excreted from the body). The BE should be regarded as an interim screening value that can be revised if and when the scientific and regulatory communities agree on acceptable concentrations in human blood or urine based directly on data from human studies.
The BE can serve as a guideline for comparison to population data for that chemical in blood or urine to evaluate the margin of safety for the population.
These pages provide additional background information on biomonitoring, exposure guidance values used as the basis for BE derivation, the process of developing BE values, and the uses and limitations of BE values.